A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern

The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose-sparing strategies. Here, we evaluate the SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a populat...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gils, Marit J., van Willigen, Hugo D.G., Wynberg, Elke, Han, Alvin X., van der Straten, Karlijn, Burger, Judith A., Poniman, Meliawati, Oomen, Melissa, Tejjani, Khadija, Bouhuijs, Joey H., Verveen, Anouk, Lebbink, Romy, Dijkstra, Maartje, Appelman, Brent, Lavell, A.H. Ayesha, Caniels, Tom G., Bontjer, Ilja, van Vught, Lonneke A., Vlaar, Alexander P.J., Sikkens, Jonne J., Bomers, Marije K., Russell, Colin A., Kootstra, Neeltje A., Sanders, Rogier W., Prins, Maria, de Bree, Godelieve J., de Jong, Menno D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668345/
https://www.ncbi.nlm.nih.gov/pubmed/35103254
http://dx.doi.org/10.1016/j.xcrm.2021.100486
_version_ 1784614552031199232
author van Gils, Marit J.
van Willigen, Hugo D.G.
Wynberg, Elke
Han, Alvin X.
van der Straten, Karlijn
Burger, Judith A.
Poniman, Meliawati
Oomen, Melissa
Tejjani, Khadija
Bouhuijs, Joey H.
Verveen, Anouk
Lebbink, Romy
Dijkstra, Maartje
Appelman, Brent
Lavell, A.H. Ayesha
Caniels, Tom G.
Bontjer, Ilja
van Vught, Lonneke A.
Vlaar, Alexander P.J.
Sikkens, Jonne J.
Bomers, Marije K.
Russell, Colin A.
Kootstra, Neeltje A.
Sanders, Rogier W.
Prins, Maria
de Bree, Godelieve J.
de Jong, Menno D.
author_facet van Gils, Marit J.
van Willigen, Hugo D.G.
Wynberg, Elke
Han, Alvin X.
van der Straten, Karlijn
Burger, Judith A.
Poniman, Meliawati
Oomen, Melissa
Tejjani, Khadija
Bouhuijs, Joey H.
Verveen, Anouk
Lebbink, Romy
Dijkstra, Maartje
Appelman, Brent
Lavell, A.H. Ayesha
Caniels, Tom G.
Bontjer, Ilja
van Vught, Lonneke A.
Vlaar, Alexander P.J.
Sikkens, Jonne J.
Bomers, Marije K.
Russell, Colin A.
Kootstra, Neeltje A.
Sanders, Rogier W.
Prins, Maria
de Bree, Godelieve J.
de Jong, Menno D.
author_sort van Gils, Marit J.
collection PubMed
description The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose-sparing strategies. Here, we evaluate the SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a population-based cohort. One week after first vaccine dose, spike protein antibody levels are 27-fold higher and neutralizing antibody titers 12-fold higher, exceeding titers of fully vaccinated SARS-CoV-2-naive controls, with minimal additional boosting after the second dose. Neutralizing antibody titers against four variants of concern increase after vaccination; however, overall neutralization breadth does not improve. Pre-vaccination neutralizing antibody titers and time since infection have the largest positive effect on titers following vaccination. COVID-19 severity and the presence of comorbidities have no discernible impact on vaccine response. In conclusion, a single dose of BNT162b2 vaccine up to 15 months after SARS-CoV-2 infection offers higher neutralizing antibody titers than 2 vaccine doses in SARS-CoV-2-naive individuals.
format Online
Article
Text
id pubmed-8668345
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86683452021-12-14 A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern van Gils, Marit J. van Willigen, Hugo D.G. Wynberg, Elke Han, Alvin X. van der Straten, Karlijn Burger, Judith A. Poniman, Meliawati Oomen, Melissa Tejjani, Khadija Bouhuijs, Joey H. Verveen, Anouk Lebbink, Romy Dijkstra, Maartje Appelman, Brent Lavell, A.H. Ayesha Caniels, Tom G. Bontjer, Ilja van Vught, Lonneke A. Vlaar, Alexander P.J. Sikkens, Jonne J. Bomers, Marije K. Russell, Colin A. Kootstra, Neeltje A. Sanders, Rogier W. Prins, Maria de Bree, Godelieve J. de Jong, Menno D. Cell Rep Med Article The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose-sparing strategies. Here, we evaluate the SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in 150 previously SARS-CoV-2-infected individuals from a population-based cohort. One week after first vaccine dose, spike protein antibody levels are 27-fold higher and neutralizing antibody titers 12-fold higher, exceeding titers of fully vaccinated SARS-CoV-2-naive controls, with minimal additional boosting after the second dose. Neutralizing antibody titers against four variants of concern increase after vaccination; however, overall neutralization breadth does not improve. Pre-vaccination neutralizing antibody titers and time since infection have the largest positive effect on titers following vaccination. COVID-19 severity and the presence of comorbidities have no discernible impact on vaccine response. In conclusion, a single dose of BNT162b2 vaccine up to 15 months after SARS-CoV-2 infection offers higher neutralizing antibody titers than 2 vaccine doses in SARS-CoV-2-naive individuals. Elsevier 2021-12-14 /pmc/articles/PMC8668345/ /pubmed/35103254 http://dx.doi.org/10.1016/j.xcrm.2021.100486 Text en © 2021. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
van Gils, Marit J.
van Willigen, Hugo D.G.
Wynberg, Elke
Han, Alvin X.
van der Straten, Karlijn
Burger, Judith A.
Poniman, Meliawati
Oomen, Melissa
Tejjani, Khadija
Bouhuijs, Joey H.
Verveen, Anouk
Lebbink, Romy
Dijkstra, Maartje
Appelman, Brent
Lavell, A.H. Ayesha
Caniels, Tom G.
Bontjer, Ilja
van Vught, Lonneke A.
Vlaar, Alexander P.J.
Sikkens, Jonne J.
Bomers, Marije K.
Russell, Colin A.
Kootstra, Neeltje A.
Sanders, Rogier W.
Prins, Maria
de Bree, Godelieve J.
de Jong, Menno D.
A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
title A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
title_full A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
title_fullStr A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
title_full_unstemmed A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
title_short A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
title_sort single mrna vaccine dose in covid-19 patients boosts neutralizing antibodies against sars-cov-2 and variants of concern
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668345/
https://www.ncbi.nlm.nih.gov/pubmed/35103254
http://dx.doi.org/10.1016/j.xcrm.2021.100486
work_keys_str_mv AT vangilsmaritj asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vanwilligenhugodg asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT wynbergelke asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT hanalvinx asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vanderstratenkarlijn asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT burgerjuditha asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT ponimanmeliawati asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT oomenmelissa asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT tejjanikhadija asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT bouhuijsjoeyh asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT verveenanouk asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT lebbinkromy asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT dijkstramaartje asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT appelmanbrent asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT lavellahayesha asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT canielstomg asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT bontjerilja asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vanvughtlonnekea asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vlaaralexanderpj asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT sikkensjonnej asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT bomersmarijek asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT russellcolina asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT kootstraneeltjea asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT sandersrogierw asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT prinsmaria asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT debreegodelievej asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT dejongmennod asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT asinglemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vangilsmaritj singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vanwilligenhugodg singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT wynbergelke singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT hanalvinx singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vanderstratenkarlijn singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT burgerjuditha singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT ponimanmeliawati singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT oomenmelissa singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT tejjanikhadija singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT bouhuijsjoeyh singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT verveenanouk singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT lebbinkromy singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT dijkstramaartje singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT appelmanbrent singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT lavellahayesha singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT canielstomg singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT bontjerilja singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vanvughtlonnekea singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT vlaaralexanderpj singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT sikkensjonnej singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT bomersmarijek singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT russellcolina singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT kootstraneeltjea singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT sandersrogierw singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT prinsmaria singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT debreegodelievej singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT dejongmennod singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern
AT singlemrnavaccinedoseincovid19patientsboostsneutralizingantibodiesagainstsarscov2andvariantsofconcern

Ejemplares similares